In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi

被引:40
作者
Garcia-Effron, G [1 ]
Gomez-Lopez, A [1 ]
Mellado, E [1 ]
Monzon, A [1 ]
Rodriguez-Tudela, JL [1 ]
Cuenca-Estrella, M [1 ]
机构
[1] Inst Salud Carlos III, Ctr Nacl Microbiol, Serv Micol, Madrid 28220, Spain
关键词
Aspergillus spp; Spanish filamentous fungi; allylamines; antifungals;
D O I
10.1093/jac/dkh228
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The activity in vitro of terbinafine against 442 clinical isolates of several species of filamentous fungi was analysed. Methods: A broth microdilution test was carried out following the National Committee for Clinical Laboratory Standards reference method, with modifications described previously. Results: The geometric mean (GM) of MICs of terbinafine for non-Aspergillus fumigatus species was 0.24 mg/L whereas the GM for A. fumigatus rose as far as 2.92 mg/L. Terbinafine showed a very strong activity in vitro against Penicillium spp., Paecilomyces spp., Trichoderma spp., Acremonium spp. and Arthrographis spp. with GMs <1 mg/L. However, some species such as Scedosporium spp., Fusarium spp., Scopulariopsis brevicaulis, and most of Mucorales exhibited high MICs of the allylamine with GMs greater than or equal to 4 mg/L. Conclusions: Overall, the GM of MICs of terbinafine was 1.57 mg/L, but significant differences in susceptibilities were seen between genera and species.
引用
收藏
页码:1086 / 1089
页数:4
相关论文
共 14 条
[1]   Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine [J].
Clark, NM .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1169-1170
[2]   Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents [J].
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Mellado, E ;
Buitrago, MJ ;
Monzón, A ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2339-2341
[3]   Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. [J].
Cuenca-Estrella, M ;
Díaz-Guerra, TM ;
Mellado, E ;
Rodríguez-Tudela, JL .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) :525-532
[4]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[5]   In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. [J].
Gomez-Lopez, A ;
Garcia-Effron, G ;
Mellado, E ;
Monzon, A ;
Rodriguez-Tudela, JL ;
Cuenca-Estrella, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3085-3088
[6]  
Hay RJ, 1999, BRIT J DERMATOL, V141, P36
[7]   Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine [J].
Howden, BP ;
Slavin, MA ;
Schwarer, AP ;
Mijch, AM .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (02) :111-113
[8]   An evaluation of the in vitro activity of terbinafine [J].
Jessup, CJ ;
Ryder, NS ;
Ghannoum, MA .
MEDICAL MYCOLOGY, 2000, 38 (02) :155-159
[9]   In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B [J].
Moore, CB ;
Walls, CM ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1882-1885
[10]  
Pfaller M.A., 2002, REFERENCE METHOD BRO